Sabinsa Corporation Overview
Sabinsa Corporation is the US commercial and marketing arm of the Sami-Sabinsa Group, a vertically integrated Indian-American health-science company that pioneered the commercialisation of standardised Ayurvedic botanical extracts in Western dietary-supplement markets. Founded in New Jersey in 1988 by pharmacist-entrepreneur Dr. Muhammed Majeed, Sabinsa built its franchise on branded, patented and clinically studied ingredients — most notably Curcumin C3 Complex®, BioPerine® black-pepper extract, Boswellin®, ForsLean® and the probiotic LactoSpore® — sold to supplement, functional-food, cosmetic and pharmaceutical manufacturers. The group markets more than 120 standardised botanical extracts, operates eleven manufacturing facilities, supports an approximately 20,000-acre cultivation programme, and derives about 95% of its business from exports. Since 2025, Sabinsa has extended downstream into finished consumer products through its Sabinsa Wellness division. It competes as a science-and-IP-led premium supplier against both global ingredient majors and low-cost Indian and Chinese extract producers.
What the company does
Sabinsa describes itself as a multinational health-science company that manufactures, supplies and markets herbal extracts, cosmeceuticals, minerals, dietary-supplement ingredients and specialty fine chemicals for the nutritional, cosmetic, pharmaceutical and food industries [S2]. Its current self-description lists botanical extracts, nutraceutical and cosmeceutical ingredients, probiotics, minerals and enzymes [S1].
Because Sabinsa is private, there is no annual-report business description. The company's recurring press-release boilerplate positions it as known for "sustainable, natural, well-researched ingredients," with emphasis on clinical substantiation, chain of custody and sustainable sourcing [S17][S20].
Business model
| Business line | Model | Customer | Evidence |
|---|---|---|---|
| Branded ingredients (core) | B2B product sales of patented/trademarked standardised extracts, probiotics, enzymes | Supplement brands, contract manufacturers, functional food & beverage makers | [S1][S20] |
| Cosmeceutical ingredients (Sabinsa Cosmetics) | B2B product sales | Personal-care and cosmetic formulators | [S22] |
| Contract manufacturing (Utah) | Fee/product manufacturing for third-party brands | Supplement brand owners | [S29][S17] |
| Finished consumer products (Sabinsa Wellness) | B2C/B2B2C via retail | Natural-products retailers, consumers | [S18][S19] |
| IP licensing | Licensing of patents/trademarks; litigation settlements converted to licences (e.g., Chemill) | Ingredient companies | [S24] |
| API / fine chemicals (group, India) | Product sales of active pharmaceutical ingredients | Pharma companies | [S26] |
Revenue mix: The split between product, service (contract manufacturing) and licensing revenue is not publicly disclosed. Independent characterisation: the overwhelming majority of revenue is product sales of ingredients; contract manufacturing and consumer products are small but strategically growing; licensing income is likely immaterial.
Value-chain position
Sami-Sabinsa is unusually vertically integrated for an ingredient company. It spans: (1) contract cultivation of raw botanicals on approximately 20,000 acres [S7]; (2) procurement (including a spice procurement division, Sami Spices, established in Cochin in 1999) [S5]; (3) extraction, fermentation and synthesis at eleven group manufacturing facilities [S5]; (4) R&D and clinical trials with 120+ senior scientists [S5]; (5) IP creation and enforcement; (6) global marketing through Sabinsa entities in the US, Europe, China, Australia and elsewhere; and (7) since 2025, finished-goods brands [S18].
Customer types and end-markets
-
Dietary-supplement brand owners and contract manufacturers (core)
-
Functional food and beverage manufacturers — many Sabinsa ingredients hold GRAS status [S17]
-
Cosmetic and personal-care formulators (e.g., Babchiol™, SabiWhite®, LactoSporin™) [S22]
-
Pharmaceutical companies (APIs from the Hassan facility) [S26]
-
Sports and active-nutrition brands (2026 focus) [S1]
-
Retailers and consumers (Sabinsa Wellness) [S18]
Independent characterisation: Sabinsa is a mid-sized, family-controlled, export-oriented botanical-ingredient specialist whose differentiation rests on brand equity, patent density and published clinical evidence rather than scale or price. Its strategic challenge is defending premium pricing against commoditised curcumin, ashwagandha and probiotic supply, which management itself acknowledges [S14].
Strategy
No annual report or investor day exists. Strategic themes are reconstructed from management statements.
Stated themes:
-
Science-led premium positioning. Management describes a long-cycle process: identifying phytonutrients, isolating actives, safety/toxicology evaluation, standardised extraction and heavy clinical investment [S34].
-
Downstream integration into consumer brands. The Nature's Formulary deal was framed as a milestone in a long-term strategy to strengthen leadership in natural products, giving Sabinsa direct consumer reach [S12][S13].
-
Manufacturing capacity expansion. Hassan facility and stated intent to build on group manufacturing capability [S8][S26].
-
US market expansion. Explicitly cited by the CEO in 2026 hiring announcements [S31].
-
Category focus. 2026 emphasis on metabolic health, women's health, longevity, liver health and active nutrition [S1][S17][S37].
-
AI-enabled clinical evidence generation. CEO's 2026 Vitafoods Asia panel on AI-driven clinical trials [S21].
-
Partnerships. CEO said in 2024 that he sees more partnerships ahead [S8].
Initiatives in the last 24 months (Oct 2024 – Oct 2026):
Medium-term financial targets: Not publicly disclosed. The only quantified historical ambition was the founder's 2020 expectation that Hassan would help double group revenue [S26] and the 2022 IPO intention [S10].
Products & Services
The group markets more than 120 standardised botanical extracts [S5][S12]. The catalogue below covers flagship branded ingredients named in company and trade sources. Pricing is not publicly disclosed for any B2B ingredient.
Nutraceutical ingredients
| Brand | Description / source material | Key positioning | Source |
|---|---|---|---|
| Curcumin C3 Complex® | Standardised curcuminoids from turmeric | Described by company as the most clinically researched curcumin ingredient; patent-protected and litigated | [S17][S25] |
| Curcumin C3 Reduct® | Tetrahydrocurcuminoids (curcumin metabolites) | Oral health, antioxidant; EFSA-approved / REACH-registered form for cosmetics | [S20][S22][S33] |
| BioPerine® | Black-pepper (piperine) extract | Bioavailability enhancer; flagship brand | [S4][S20] |
| Boswellin® | Boswellia serrata extract | Joint health | [S4] |
| ForsLean® | Coleus forskohlii extract | Weight management/body composition | [S4] |
| Shagandha™ | Ashwagandha extract | Stress/adaptogen | [S4][S20] |
| Saberry® | Amla (Emblica officinalis) extract | Antioxidant, metabolic health; used in Sanutra products | [S4][S17] |
| Sabeet® | Beetroot extract | Nitric oxide/active nutrition; 2026 trial in postmenopausal women | [S1][S3x] |
| LactoSpore® | Bacillus coagulans spore probiotic | Gut health; Best Technology Innovation award, ChengDu | [S4] |
| DigeZyme® | Multi-enzyme complex | Digestive support | [S20] |
| Sabroxy® | Oroxylum indicum extract | Cognitive support | [S20] |
| Nigellin® | Black-seed (Nigella sativa) extract | Immune/metabolic | [S20] |
| LivLonga® | Combination of two clinically studied ingredients | Liver support; preclinical-to-clinical programme | [S20][S34] |
| Silbinol® | Pterostilbene-based ingredient | Healthy ageing; used in Sanutra | [S17] |
| pTeroSol® | Water-soluble Pterocarpus marsupium | Blood-sugar management | [S35] |
| NiLitis® | Joint-health ingredient | Joint support | [S35] |
| Macumax® | Eye-health ingredient | Early dry-type AMD study (40 subjects, 90 days, open-label) | [S36] |
| Cococin® | Coconut-water-derived ingredient | Featured at SAPHEX 2026 | [S3x] |
| PoZibio® | Postbiotic ingredient | Featured at SAPHEX 2026 | [S3x] |
| Picroliv® | Picrorhiza kurroa extract | Liver support; featured in Nature's Formulary | [S20] |
[S3x] = sabinsa.com SAPHEX 2026 event page (see source list S37).
Cosmeceutical ingredients
| Brand | Description | Source |
|---|---|---|
| LactoSporin™ | Postbiotic for skin renewal | [S22] |
| Cosmoperine® | Tetrahydropiperine penetration enhancer | [S4] |
| Babchiol™ | Retinol alternative, ≥99% bakuchiol from Psoralea corylifolia | [S22] |
| SabiWhite® | Tetrahydrocurcuminoid skin-brightening active | [S22] |
| pTeroWhite® | Pterocarpus-derived brightening ingredient | [S22] |
| Artonox® | Antioxidant cosmetic active | [S22] |
Consumer brands (Sabinsa Wellness)
| Brand | Positioning | Flagship content | Source |
|---|---|---|---|
| America's Finest, Inc. (AFI) | Science-based supplements | Curcumin C3 Complex products | [S17][S20] |
| Sanutra Wellness | Healthy ageing / baby-boomer demographic | Saberry, Silbinol formulations | [S17] |
| Nature's Formulary | Premium Ayurvedic products (founded c.1993) | Ashwagandha, Picrorhiza/Picroliv | [S18][S20] |
All Wellness products are made in the USA at the Utah contract-manufacturing facility [S17].
Services
| Service | Description | Source |
|---|---|---|
| Contract manufacturing | Finished dosage manufacturing in Utah | [S17] |
| Regulatory/dossier support | Full safety, toxicology, clinical and specification dossiers per ingredient; country-specific regulatory guidance | [S21][S34] |
| Education | Web seminars (e.g., LactoSpore, weight management), "Sabinsa on Wheels" (South Korea), Knowledge Days (Paris 2026) | [S10b][S37] |
Financial Narrative
Disclosure status: Sabinsa Corporation and Sami-Sabinsa Group Limited do not publish audited financial statements in the public domain. The only management-disclosed figure is group revenue "over ₹1,200 crore" for FY2022 [S10]. All other cells are left blank (not publicly disclosed).
Income statement: notes and sources
Note: FY2022 figure is "over ₹1,200 crore" (₹12,000 million) per founder interview, The Hindu BusinessLine, 14 Jul 2022 [S10]; treat as a floor, not an audited number.
Disclosed capital investment
Separately, in July 2022 the group cited a ₹300 crore (₹3,000 million) investment in two manufacturing facilities [S10]. Whether this overlaps the US$30M Hassan figure is not disclosed.
Commentary
In the absence of audited financials, analysis is necessarily qualitative. Three inferences are reasonably supported. First, scale: at roughly ₹1,200 crore (~US$155–160M) in FY2022, the group is a mid-sized specialist — an order of magnitude smaller than diversified ingredient majors such as Givaudan or Kerry. Second, capital intensity rose meaningfully in FY2020–FY2023 with the Hassan greenfield build, which the founder expected would help "double" revenue [S26]; no subsequent disclosure confirms whether that trajectory materialised. Third, the business is structurally export-dependent (~95% exports) [S10], meaning reported INR revenue benefits from rupee depreciation against the dollar and euro, while US tariff and regulatory changes are direct exposures. Revenue CAGR cannot be computed. The 2022 statement that an IPO was "underway in the next two years" [S10] has not, to our knowledge, resulted in a DRHP filing with SEBI; the founder's death in March 2024 and leadership transition are plausible reasons for deferral, but the company has not stated this.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Role | Location |
|---|---|---|
Sami-Sabinsa Group Limited (formerly Sami Labs Ltd) | Parent; R&D; manufacturing | Bengaluru, India |
Sabinsa Corporation | US marketing, sales, scientific affairs | East Windsor, NJ |
Sabinsa Utah (contract manufacturing) | Finished-goods manufacturing; Sabinsa Wellness production | Payson, Utah |
Sabinsa Wellness (consumer goods division) | America's Finest Inc. (AFI), Sanutra Wellness, Nature's Formulary | US |
Sabinsa Cosmetics | Cosmeceutical ingredients | NJ-based division |
Sami Nutraceuticals Pvt. Ltd. | Hassan greenfield facility (Unit-1) | Hassan, India |
Sami Spices | Spice procurement and marketing | Cochin, India |
Sabinsa Nanjing Biotechnology Co. Ltd. | China operations | Nanjing, China |
Sabinsa Europe (incl. France, Poland, UK offices) | European sales | Europe |
Sabinsa Australia | Australia/NZ sales; TGA listings | Australia |
Segment (Analyst-defined) Overview
| Segment (analyst-defined) | Contents | Revenue disclosed? |
|---|---|---|
Nutraceutical ingredients | Botanical extracts, probiotics, enzymes, minerals | No |
Cosmeceutical ingredients | Skin, oral-care and nutricosmetic actives | No |
APIs / fine chemicals | Patented and off-patent APIs from Hassan | No |
Contract manufacturing | Utah facility services | No |
Consumer wellness | AFI, Sanutra, Nature's Formulary | No |
Income Statement
| Metric | FY2022 |
|---|---|
Revenue (INR Mn) | 12,000 |
Estimate Details
| Estimate (USD Mn) | Value | Provider | Note |
|---|---|---|---|
Sami-Sabinsa Group Ltd annual revenue | 158.7 | Prospeo [S9] | Consistent with ₹1,200 crore at ~₹75–76/USD |
Sabinsa (US) annual revenue range | 100–500 | Owler [S16] | Range only |
Capex item (USD Mn)
| Capex item (USD Mn) | FY2020 |
|---|---|
Hassan API facility planned investment | 30 |
Region Revenue (% of group)
| Region Revenue (% of group) | FY2022 |
|---|---|
Exports (all non-India) | 95 |
India domestic | 5 |
Region Overview
| Region | Assessment | Evidence |
|---|---|---|
North America | Largest and most mature market (inferred); management explicitly targeting expansion of US presence in 2026 | US hiring of Director of Business Development; CEO Americas role [S30][S12] |
Europe | Active expansion: offices in UK, France, Poland; President of European Operations appointed; Paris Knowledge Day 2026 | [S23][S24][S37] |
China / East Asia | Nanjing subsidiary relocated to new facility; Hi & Fi Asia-China 2026; Sabinsa on Wheels South Korea | [S23][S37] |
Southeast Asia | Vitafoods Asia 2026 with APAC-specific regulatory positioning | [S21] |
Africa | SAPHEX 2026 Johannesburg presence signals South African market development | [S37] |
Australia / NZ | Sabinsa Australia with TGA listing effort | [S32] |
India domestic | Small share (~5%) but founder called domestic market a growth opportunity; CEO keynote at Bharat Nutraverse 2026 | [S10][S1] |
Capital Markets
| Item | Status |
|---|---|
Share price performance (1/3/5-yr) | Not applicable — private |
External funding | None raised per Prospeo [S9] |
IPO status | Announced intention (2022); no filing identified [S10] |
Capital Markets Metric | FY2022 |
Analyst Conclusions
Management guidance: None published. Directional signals: US market expansion, consumer-brand growth, manufacturing build-out and partnerships [S8][S31].
Consensus: None (no coverage).
Bull case
-
Defensible premium niche: a clinical-evidence moat (C3 Complex, BioPerine, LactoSpore) plus fresh 2026 data (Sabeet) supports pricing as regulators demand documentation.
-
Integration upside: cultivation-to-consumer value chain allows margin capture as Sabinsa Wellness scales.
-
Optionality: Hassan API capacity and a still-possible IPO could re-rate the group.
Bear case
-
Commoditisation: management itself concedes customers trade down to cheaper supply.
-
Concentration: ~95% export dependence and family-concentrated governance amplify trade and succession shocks.
-
Execution drift: the 2020 revenue-doubling and 2022 IPO ambitions have no public evidence of delivery.
Catalysts and monitorables (next 12 months)
-
SupplySide Global, 28–30 October 2026: new ingredient launches and study announcements
-
Retail traction of Sabinsa Wellness brands
-
Any SEBI DRHP filing or strategic-investor announcement
-
Further acquisitions in consumer wellness
-
US tariff treatment of Indian botanical imports
-
Publication of additional clinical trials (women's health, liver, active nutrition)
-
Outcome of CSIR-NIIST collaboration discussions
Analyst verdict
Sabinsa Corporation is not the public company our list suggests; it is the US face of the privately held, Majeed family-controlled Sami-Sabinsa Group, and any assessment must be made through that lens. On the evidence available, the business is a credible, mid-sized, science-led specialist with an enviable portfolio of branded botanical ingredients — several of which effectively defined their categories in Western supplement markets — supported by a large patent estate, a substantial in-house scientific workforce and genuine vertical integration from field to extract.
The 2024 death of founder Dr. Muhammed Majeed was the most consequential event in the company's history. The succession to Dr. Anju Majeed and Dr. Shaheen Majeed appears orderly, and the new leadership has been more commercially assertive than its predecessor: it bought its first consumer brand within ten months, reorganised the Americas sales leadership, pushed into new geographies, and is positioning the company in growth themes such as women's health, longevity and active nutrition.
The constraints are equally clear. Sabinsa competes against multinationals many times its size and against low-cost producers, and management openly admits price-driven defections. Its export concentration exposes it to trade policy, and the move into finished goods risks irritating the very brand customers that buy its ingredients. Most importantly for an outside analyst, the absence of any audited financial disclosure since a single FY2022 revenue figure makes it impossible to test whether the heavy capital programme at Hassan has delivered the promised growth.
Our verdict: Sabinsa is a strategically sound, IP-rich franchise in a structurally growing market, best characterised as a "quality but opaque" counterparty. For partners and suppliers, risk is moderate. For any prospective investor, the critical unknowns — revenue trajectory since FY2022, margins, leverage and IPO timing — must be resolved through MCA filings or direct diligence before conviction can be formed.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure / start | Background | Education |
|---|---|---|---|---|
Dr. Anju Majeed | Group Executive Chairperson | Since 1 Apr 2024 | Formerly Group Director and Senior Scientist; led API manufacturing, process R&D, pre-formulation, pilot plant teams | BS/MS Rutgers (microbiology, molecular genetics); MS Johns Hopkins; PhD Microbiology, Bharathidasan University; NIH Research Fellow 2001–05 |
Dr. Shaheen Majeed | Global CEO & Managing Director; board member | Since 1 Apr 2024 | ~25 years at Sabinsa (sales, supply chain, manufacturing, global marketing; 4 years President Worldwide); briefly CEO of three BGG World subsidiaries (HB Natural Ingredients USA, BGG Americas, Algae Health Sciences) | MBA; D.Litt. (honorary) |
Asha Ramesh | CEO, Americas | CEO Sabinsa USA from Oct 2018; CEO Americas from Jan 2025 | 20+ years in group; previously VP Business Development; joined Sabinsa staff Jan 2000 | — |
P K Davé | CEO, Consumer Goods Division (Sabinsa Wellness) | Since Feb 2025 | Founder/president of Nature's Formulary | — |
Dr. Umar Jan | President, European Operations | — | — | — |
Jan Obirek | VP Sales, US & Canada | Since Jan 2025 | — | — |
Madhu Subramanian | Global Business Expansion & Operations | — | — | — |
Dr. K Srinivasa Reddy | Group Director, Quality & Regulatory | Re-joined (date not disclosed) | Former Director of Quality, OmniActive Health Technologies | — |
Jeanette Fisher, RDN | Marketing Director | — | ~20 years at Soft Gel Technologies | RDN |
Darrin Fox | VP Operations, Sabinsa Utah | — | — | — |
Dr. Alphons Philips | Director, Scientific Affairs | — | — | — |
Brandon Prenger | Director of Business Development | 2,026 | 20+ years: INS, SpecNova, Nutragenesis/Innophos, Deerland Enzymes, National Enzyme Co. | BS Animal Science, Southern Illinois University |
Dr. Kalyanam Nagabhushanam | President, R&D (last reported) | — | Presented at FDA CDER Botanical Drug Seminar Series | — |
“—” = not publicly disclosed.
Directors' Remuneration
| Item | Status |
|---|---|
Executive compensation | Not publicly disclosed (no proxy statement) |
Board composition / independence | Not publicly disclosed; Shaheen Majeed and Anju Majeed confirmed directors; Asha Ramesh joined Sabinsa (US) board in 2018 [S28] |
Chair/CEO separation | Yes at group level — Executive Chairperson (Anju Majeed) separate from Global MD & CEO (Shaheen Majeed); both are siblings, so separation is not independence |
Institutional ownership | None disclosed; company has "never raised funding" per Prospeo [S9] |
Insider ownership | Believed majority family-controlled (Majeed family); exact stakes not publicly disclosed |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
13 Mar 2024 | Death of founder/chairman Muhammed Majeed | Key-person event after 36 years of leadership [S3] |
1 Apr 2024 | Anju Majeed Executive Chairperson; Shaheen Majeed Global MD & CEO | Second-generation succession [S7] |
Jan 2025 | Asha Ramesh CEO Americas; Jan Obirek VP Sales | Commercial reorganisation [S12] |
Feb 2025 | P K Davé CEO Consumer Goods | Integration of Nature's Formulary [S14] |
| 2026 | Brandon Prenger Director of Business Development | US growth push [S30] |
Competitive Landscape
Key Competitors
| Competitor | HQ | Ownership | Overlap with Sabinsa |
|---|---|---|---|
OmniActive Health Technologies | India | Private | Curcumin, lutein, botanical actives |
Naturex (part of Givaudan) | France/Switzerland | Listed (Givaudan) | Botanical extracts |
Indena | Italy | Private | Botanical extracts incl. curcumin phytosome |
Arjuna Natural | India | Private | Curcumin, ashwagandha |
Natreon | USA/India | Private | Ayurvedic extracts (ashwagandha, amla) |
dsm-firmenich (DSM) | Netherlands/Switzerland | Listed | Vitamins, nutrition ingredients |
Roquette | France | Private | Plant-based ingredients |
Ganeden (now Kerry) | Ireland | Listed (Kerry Group) | Bacillus coagulans probiotics vs LactoSpore |
Novel Ingredient | USA | Private | Branded botanicals |
SCD Probiotics | USA | Private | Probiotics |
NOW Foods | USA | Private | Finished supplements (vs Sabinsa Wellness) |
Garden of Life (Nestlé Health Science) | USA | Listed parent | Finished supplements |
Competitor Detail
| Metric | Sabinsa (group) |
|---|---|
Revenue | ~₹1,200 crore (FY2022, mgmt.) |



